Technical Articles

As a critical member of the immunoglobulin superfamily, MYD1 protein (SIRP alpha/SHPS1) serves both as a key receptor for cell surface signaling regulation and a core participant in tumor microenvironment remodeling. Its unique structural features and interactions with the Gas6/AXL signaling pathway offer novel targeting strategies for cancer therapy. This review systematically analyzes MYD1's three-dimensional conformation, signal transduction networks, and its bidirectional regulatory mechanisms in tumor immunology, with a focus on the clinical potential of the high-affinity mutant MYD1-72. The findings provide theoretical foundations for developing next-generation anticancer therapeutics.